https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-accord 2022 false false false Netherlands French English drugs, generic treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation metformin and sitagliptin hypoglycemic agents incretins dipeptidyl-peptidase iv inhibitors drug combinations metformin Metformin Hydrochloride sitagliptin diabetes mellitus, type 2 drug approval europe
--- https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-accord 2022 false false false Netherlands French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation sitagliptin sitagliptin sitagliptin drugs, generic
--- https://www.has-sante.fr/jcms/p_3376996/fr/sitagliptine/metformine-alter-sitagliptine-/-metformine 2022 false false false France adult diabetes mellitus, type 2 treatment outcome insurance, health, reimbursement drug combinations sitagliptin metformin administration, oral hypoglycemic agents metformin and sitagliptin Product containing only metformin and sitagliptin in oral dose form (medicinal product
form) dipeptidyl-peptidase iv inhibitors Metformin Hydrochloride evaluation of the transparency committee
--- https://www.has-sante.fr/jcms/p_3282764/fr/xelevia-sitagliptine 2021 false false false France evaluation of the transparency committee Sitagliptin Phosphate sitagliptin administration, oral treatment outcome diabetes mellitus, type 2 Product containing precisely sitagliptin (as sitagliptin phosphate) 25 milligram/1
each conventional release oral tablet (clinical drug) hypoglycemic agents incretins dipeptidyl-peptidase iv inhibitors
--- http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67935602 2012 France summary of product characteristics package leaflet sitagliptin tablets metformin
--- http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62214025 2012 France summary of product characteristics package leaflet sitagliptin tablets metformin